Pre-Liver Transplant: Tips Versus Distal Splenorenal Shunt by Faust, Thomas W. & Sorrell, Michael F.
HPB INTERNATIONAL 261
[5] Scheele, J., Stangl, R., Altendorf-Hofmann, A. and Paul,
M. (1995). Resection of colorectal liver metastases. World
Journal of Surgery, 19, 59-71.
[6] Doci, R., Gennari, L., Bignami, P., Montalto, F., Morabito,
A. and Bozzetti, F. (1991). One hundred patients with
hepatic metastases from colorectal cancer treated by
resection: analysis of prognostic determinants. British
Journal of Surgery, 78, 797-801.
[7] Yanaga, K., Kanematsu, T. and Takenaka, K. et al. (1988).
Hepatic resection for hepatocellular carcinoma in elderly
patients. American Journal of Surgery, 155, 238-241.
[8] Fortner, J.G. and Lincer, R.M. (1990). Hepatic resection
in the elderly. Annals of Surgery, 211, 141-145.
[9] Nagasue, N., Chang, Y.C. and Takemoto, Y. et al. (1993).
Liver resection in the aged (seventy years or older) with
hepatocellular carcinoma. Surgery, 113, 148-154.
O. J. Garden, MD, FRCS
Senior Lecturer in Surgery
Director of Organ Transplantation
University Department of Surgery
Royal Infirmary, Lauriston Place
Edinburgh
United Kingdom
Pre-Liver Transplant: Tips Versus
Shunt
Distal Splenorenal
ABSTRACT
Abouljoud, M.S., Levy, M.F., Rees, C.R., Diamond,
N.G., Lee, S.P., Mulligan, D.C., Goldstein, R.M.,
Husberg, B., Gonwa, T.A. and Klintmalm, G.B.
(1995)A comparison of treatment with transjugular
intrahepatic portosystemic shunt or distal splenor-
enal shunt in the management of variceal bleeding
prior to liver transplantation. Transplantation, 59:
226-229.
Recurrent variceal bleeding in liver transplant
candidates with end-stage liver disease can
complicate or even prohibit a subsequent
transplant procedure (OLT). Endoscopic
sclero-therapy and medical therapy are consi-
dered as first-line management with surgical
shunts reserved for refractory situations. Surgi-
cal shunts can be associated with a high
mortality in this population and may compli-
cate subsequent OLT. The transjugular intra-
hepatic portosystemic shunt (TIPS) has been
recommended in these patients as a bridge to
OLT. This is a new modality that has not been
compared with previously established thera-
pies such as the distal splenorenal shunt
(DSRS). In this study we report our experience
with 35 liver transplant recipients who had a
previous TIPS (18 patients) or DSRS (17
patients) for variceal bleeding. The TIPS group
had a significantly larger proportion of criti-
cally ill and Child-Pugh C patients. Mean
operating time was more prolonged in the
DSRS group (P=0.014) but transfusion require-
ments were similar. Intraoperative portal vein
blood flow measurements averaged 2132+/-725
ml/min in the TIPS group compared with
1120+/-351ml/min in the DSRS group (P<0.001).
Arterial flows were similar. Mean ICU and
hospital stays were similar. There were 3
hospital mortalities in the DSRS group and
none in the TIPS group (P=0.1). We conclude
that TIPS is a valuable tool in the management
of recurrent variceal bleeding prior to liver
transplantation. Intra0Perative hemodynamic
measurements suggest a theoretical advantage
with TIPS. In a group of patients with advanced
liver disease we report an outcome that is
similar to patients treated with DSRS prior to
liver transplantation. The role of TIPS in the
treatment of nontransplant candidates remains
to be clarified.262 HPB INTERNATIONAL
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PAPER DISCUSSION
The paper by Abouljoud, et al. describes their
experience with the use of transjugular intrahe-
patic portosystemic shunt (TIPS) in a busy
transplant service and compares distal spleno-
renal shunts (DSRS) to TIPS relative to post-
transplant outcome. Variceal bleeding in patients
with portal hypertension is a frequent finding in
patients with end stage liver disease[I-4]. It is
critically important to assess risk factors for
bleeding and to use preventive strategies in the
evaluation and management of patients with
known varices in the patient awaiting transplan-
tation since variceal bleeding may exclude or
complicate liver transplantation. Therapeutic
options for treatment ofbleeding esophagogastric
varices and prevention of rebleeding should be
structured to optimize patient outcome and
assure successful transplantation.
Risk factors for predicting hemorrhage from
varices have been well defined. Variceal size,
intravariceal pressure, red color signs and the
Child Pugh classification of liver disease are
important variables in the evaluation of patients
at risk for hemorrhage[5]. Lebrec et al. have
shown that a portal or hepatic venous pressure
gradient of at least 12 mm Hg is required for the
developement of hemorrhage from esophageal
varices, but that gradations in pressure above 12
mm Hg are not associated with a proportional
increase in bleeding risk [6].
Prevention of variceal bleeding is important
because mortality dramatically increases after
bleeding occurs. Non-selective beta blockers may
beused to prevent the first varicealhemorrhage in
patients with end stage liver disease; patients
with decompensated liver disease andmedium to
large varices are most likely to benefit[7,8].
Prevention of initial variceal hemorrhage through
shunt surgery is not beneficial. Prophylatic
sclerotherapy of varices is also not an effective
preventive strategy [8,9]. Patients with end stage
liver disease who bleed from esophageal varices
warrant aggressive treatment to control the initial
bleed and to prevent rebleeding. Acute bleeding
may be controlled endoscopically with either
sclerotherapy or band ligation[2-4,10]. Endo-
scopic ligation of varices controls acute bleeding
as effectively as sclerotherapy, but with fewer
complications, reduced rebleeding rates, and
possibly improved survival [10]. Well-known
complications associated with endoscopic treat-
ment include esophageal ulceration or perfora-
tion, cardiopulmonary sequelae, and infections,
all of which may preclude transplantation or
increase operative risk [10-12]. Additionally, va-
soactive agents may be used for the aute
treatment of bleeding varices [13]. Vasopressin
with nitroglycerin, glypressin, somatostatin, and
octreotide may effectively control variceal he-
morrhage, but only glypressin has been shown to
significantly improve survival. In the patientwho
has recovered from a variceal bleed, the addition
of non-selective beta blockers to endoscopic
therapy reduces rebleeding rates when compared
to either therapy alone but mortality rates may
not be significantly improved [14,15].
What options are available for patients who
continue to experience variceal bleeding despite
sclerotherapy, variceal ligation and pharmaco-
logic intervention? Both DSRS and TIPS control
variceal hemorrhage and prevent rebleeding in
over 90% of cases. As with all therapies, risks
and benefits must be carefully considered.
Rebleeding rates and patient survival are not
significantly different between selective and
non-selective shunts but the incidence of hepatic
encephalopathy may be less in patients receiving
DSRS [16-181.
TIPS controls acute variceal bleeding and pre-
vents rebleeding in patients refractory to stan-
dard medical and endoscopic therapy.[19-22]
TIPS has been associated with a variety of
complications [20-22]. Fifteen to 66% of patients
may develop shunt stenosis or occlusion andHPB INTERNATIONAL 263
recurrent variceal bleeding within I year follow-
ing TIPS placement. Seven to 30% of patients may
experience new or worsening encephalopathy. In
addition, improperly placed TIPS may also
increase the difficulty of the transplant opera-
tion [23]. Potential complications resulting from
TIPS should be carefully considered, keeping in
mind the effect that complications may have on
candidacy for liver transplant. TIPS is a short-
term solution for the prevention of recurrent
hemorrhage in patients with end stage liver
disease who are candidates for transplantation.
What factors are important to consider in
management of the potential transplant candi-
date with variceal hemorrhage? Several factors
including the clinical status of the patient, the
etiology and severity of liver disease, and
candidacy for liver transplantation should be
assessed before shunting or placement of TIPS.
The etiology of liver disease influences survival
of the patient with variceal bleeding. Patients
with cholestatic liver disease tolerate variceal
bleeding better than those with parenchymal
liver disease [24,25]. Severity of liver disease is
important in determining whether to use DSRS
or TIPS. Survival in patients with compensated
liver disease receiving DSRS for variceal bleed-
ing is superior to that of patients with decom-
pensated liver disease [26]. Survival in patients
who are treated with DSRS in the setting of
mild to moderate liver disease is comparable to
that of patients receiving allografts for a similar
degree of liver failure, but patients with decom-
pensated liver disease benefit more from trans-
plantation[27,28]. Surgical shunting should be
reserved for patients with compensated liver
disease and hemorrhage refractory to nonsur-
gical methods. TIPS followed by timely trans-
plantation should be considered for patients
with refractory variceal bleeding in the setting
of decompensated liver disease [19,20].
While transplantation is an effective therapy
for end-stage liver disease; management of
variceal hemorrhage needs to be carefully
individualized to optimize patient outcome after
transplantation. Abouljoud et al. describe their
data comparing TIPS and DSRS in regards to
safety, efficacy, long-term complications and
influence on subsequent liver transplantation.
Outcome parameters included operating time,
number of transfusions, intraoperative portal
venous and hepatic arterial flow measurements;
length of stay and operative mortality was also
assessed. Mean operating time was significantly
longer in the DSRS group but there, was no
significant difference in transfusion require-
ments or cold ischemia times between the
groups. Portal venous flow was significantly
reduced in patients receiving DSRS compared to
patients receiving TIPS but there was no
significant difference in hepatic arterial flow
between the groups. Analysis of the data
demonstrated that patients undergoing TIPS
has a similar post-operative course in terms of
mortality, ICU and hospital stay compared to
those patients who had DSRS even though they
had significantly worse liver disease. Although
not statistically significant, it is worth noting that
3 deaths occurred in the DSRS population and
no deaths occurred in the TIPS group. The
authors conclude that TIPS is a valuable tool in
the management of patients with severe end
stage liver disease awaiting transplantation who
present with variceal hemorrhage.
A number of questions regarding methodo-
logy are raised in reviewing the paper by
Abouljoud and colleagues that if clarified
would be helpful in further defining the role
of DSRS vs TIPS as adjunctive therapy in the
potential transplant patient. The definition of
refractory variceal hemorrhage was not pro-
vided. The authors state that follow-up ranged
from 1-96 months. It would be helpful to
know the duration of follow-up prior to and
after liver transplantation. Recent studies sug-
gest that 30 day post-TIPS survival in the non-
transplant candidate with Child-Pugh class C
liver disease and variceal bleeding is consider-
ably worse when compared to that in patients
with milder liver disease [29,30]. TIPSfollowed264 HPB INTERNATIONAL
by timely transplantation in this patient popu-
lation reduces mortality rates; this may account
for the promising results in patients with
Child-Pugh class C liver disease receiving TIPS.
What practical conclusions can we draw from
Abjoulboud’s experience? Their data would
suggest that the use of TIPS can safely serve as
a bridge to transplantation and is particularly
useful in the patient with advanced liver disease.
Although the numbers were too small to draw
firm statistical conclusions, there were three
hospital mortalities in the DSRS group and none
in the TIPS group even though there was a larger
proportion of critically ill and Child-Pugh class
C patients in the TIPS group. However, the role
of DSRS in the treatment of variceal hemorrhage
should not be minimized. In the patient with
relatively well preserved synthetic function and
recurrent variceal hemorrhage, DSRS is a time-
tested, proven and effective treatment. The
application of a less-invasive treatment modality
in the hemorrhaging liver patient adds another
alternative to our arsenal of therapeutic options.
As is the case in all studies of new treatment
modalities, the study suffers from small num-
bers in each group. While the results of
Abouljoud and colleagues are encouraging a
larger, prospective, randomized, controlled trial
comparing endpoints of efficacy and safety of
DSRS and TIPS would be helpful in defining
standards of practice in the patient awaiting
transplantation.
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Is Hepatectomy Necessary in Dealing with Left
Hepatolithiasis with Intrahepatic Duct Stricture?
ABSTRACT
Sheen-Chen, S-M., Cheng, Y-F., Chou, F-F. and Lee,
T-Y. (1995). Ductal dilatation and stenting make
routine hepatectomy unnecessary for left hepato-
lithiasis with intrahepatic biliary stricture. Surgery;
117: 32-36.
Background: Hepatolithiasis with intrahepatic
biliary strictures, more common in Southeast
Asia than elsewhere, remains a difficult pro-
blem to manage. Hepatic resection has recently
been advocated as one of the treatment mod-
alities for hepatolithiasis; however, this proce-
dure is not without risk. This study was
designed to achieve complete clearance of the
stones, eliminate bile stasis, and avoid the
potential risks of hepatic resection in the
patient with hepatolithiasis and intrahepatic
biliary stricture.
Methods: In this prospective clinical trial 13
patients with retained left hepatolithiasis and
intrahepatic biliary strictures were included.
All the patients met the following criteria: (1)
initial surgical procedure for hepatolithiasis,
(2) normal gross findings of the left liver, and